Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical development for treatment of hematologic malignancies. CC-486 administered for 7 days per 28-day treatment cycle was evaluated in a phase 1 dose-finding study. AZA has a short...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Manero, G, Gore, S D, Kambhampati, S, Scott, B, Tefferi, A, Cogle, C R, Edenfield, W J, Hetzer, J, Kumar, K, Laille, E, Shi, T, MacBeth, K J, Skikne, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832070/
https://www.ncbi.nlm.nih.gov/pubmed/26442612
http://dx.doi.org/10.1038/leu.2015.265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832070/
https://www.ncbi.nlm.nih.gov/pubmed/26442612
http://dx.doi.org/10.1038/leu.2015.265

Ejemplares similares